Klineova 2020.

Study characteristics
Notes	English title Covid‐19 infection in patients with multiple sclerosis: an observational study by the New York COVID‐19 Neuroimmunology Consortium (NYCNIC) Study setting Start of study recruitment (MM/YYYY) NR End of study recruitment (MM/YYYY) NR Study design prospective cohort Study centre(s) multiple centres/clinics/areas within a country Number of centres/clinics/areas 5 Study setting outpatient and inpatient Number of participants recruited 349 Sampling method unspecified Participants Female participants (percentage), 70.8 Age measure, value median (range), 45 (13, 76) Inclusion criteria Patients with MS or related disorders, who self‐identified as diagnosed with COVID‐19 by a healthcare provider (based on characteristic symptoms, radiographic findings and/or positive COVID‐19 PCR/serology when available) were included. Exclusion criteria NR Smoking NR Diabetes (unspecified) Hypertension (unspecified) Cardiovascular diseases (unspecified) Please indicate if additional information is available  NR Asthma (unspecified) Chronic obstructive pulmonary disease (unspecified) Other pulmonary diseases (unspecified) Please indicate if additional information is available  NR Immunosuppression (unspecified) Please indicate if additional information is available NR Chronic kidney disease (unspecified) Cancer (unspecified) Steroid administration (unspecified) Supplemental oxygen (unspecified) Differential values for various oxygenation methods (if indicated) NR Other treatment NR Dose if applicable NR Duration if applicable NR Percentage received this treatment NR Prognostic factor(s) Study’s definition for obesity NR The time when obesity has been measured unspecified Main variable used for determination of obesity NR Threshold used for definition of obesity  NR Measure of frequency NR Frequency value NR How many eligible outcomes reported? 1 How many eligible outcomes reported? 1 Outcome(s) hospitalisation Outcome (prognostic factor) Hopitalisation (obesity) Outcome Hospitalisation Prognostic factor (category):  Obesity Follow‐up Number of patients followed completely for this outcome  349 Number of obese patients followed completely for this outcome  NR Number of non‐obese patients followed completely for this outcome  NR Univariable (unadjusted) analysis for obesity Effect measure for obesity NR Effect measure value (95% CI) NR (NR, NR) Multivariable (adjusted) analysis for obesity Modelling method logistic regression The set of prognostic factors used for adjustment Age, obesity, EDSS, race, ethnicity, comorbidities (cardiac, pulmonary, diabetes), smoking status, specific DMT Effect measure for obesity odds ratio  Effect measure value (95% CI) 2.4 (1.1, 4.9)
Item	Authors' judgement	Support for judgement
Study Participation	Unclear	Appendix 3
Study Attrition Hospitalisation	Yes	Appendix 3
Prognostic Factor Measurement	No	Appendix 3
Outcome Measurement Hospitalisation	Yes	Appendix 3
Confounding Bias Hospitalisation	Unclear	Appendix 3
Statistical Analysis Bias	Unclear	Appendix 3